Biogen shows its IgAN hand with felzartamab data
Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class t
Newsletters and Deep Dive digital magazine
Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class t
Novartis is cueing up a new indication in the US for its oral therapy for complement-mediated diseases – Fabhalta – after reporting new data with the drug in ultra-rare kidney disease C3 gl
11-12 November 2024 in London, UK
Excitement for mRNA therapeutics continues, as RNA technologies are awarded the Nobel Prize for the second year running.
GSK has made another investment in its manufacturing network, setting aside $800 million to build two plants at its Marietta site in the US.
Editor's Picks
Newsletters and Deep Dive
digital magazine